A commercial vendor received two AAV samples, one serotype 5 (AAV5) and one serotype 9 (AAV9). The two samples were generated ...

The global viral vectors and plasmid DNA manufacturing market was valued at $918.37 million in 2019, and is estimated to reach at $4,978.54 million by 2027, registering a CAGR of ...

Some cell manufacturing sites models do work closer to the Medical Center. Leger highlighted CTMC, a joint venture partially ...

Viral Vector Development MarketThe Viral Vector Development Market is set for impressive growth, with its valuation expected to rise from USD 730.7 million in 2023 to USD 4.1 billion by 2033, ...

Among these sensors, we further focused on the spatiotemporal dynamics of Rab10 and Rab4 activity during sLTP. We found that postsynaptic stimulation leads to the persistent inactivation of Rab10 and ...

Prepare plasmid DNA using standard miniprep protocols ... before plating on kanamycin-containing media. Purify the vector products by electrophoresis through 0.8–1% agarose and determine ...

Genetic Immunity, a leader in plasmid DNA-based immunotherapies, and VectorBuilder, a global specialist in gene delivery solutions, announced a strategic partnership to advance Genetic Immunity's ...

VectorBuilder, a global leader in gene delivery solutions, is excited to announce that it's received the BioIndustrial Innovation of the Year award by the BioTech Breakthrough Awards. The recognition ...

Next-generation sequencing allows for critical insights into gene therapy products, which can help streamline and accelerate ...

The phase 2 AQUAx2 study (NCT05926765) continues to enroll and dose participants at multiple sites in the U.S., Canada, and ...

Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT) ...